| Erbitux (cetuximab) / Eli Lilly |
NCT00055419: A Study of Cetuximab in Patients Who Have Stage IV Colorectal Cancer |
|
|
| Completed | 2 | 744 | US | Cetuximab, Erbitux | Eli Lilly and Company, Bristol-Myers Squibb | Colorectal Neoplasms | 07/04 | 08/04 | | |
NCT00251186: First-Line Capecitabine and Cetuximab for Metastatic Colorectal Ca in Elderly Patients |
|
|
| Terminated | 2 | 18 | US | Capecitabine and Cetuximab | University of Medicine and Dentistry of New Jersey, Rutgers Cancer Institute of New Jersey, Bristol-Myers Squibb | Colorectal Cancer | 04/06 | 04/06 | | |
NCT00362102: A Phase II Study of Cetuximab Plus Irinotecan in Patients With EGFR-detectable Metastatic Colorectal Carcinoma |
|
|
| Completed | 2 | 38 | Japan | Cetuximab | Eli Lilly and Company | Colorectal Carcinoma | 07/06 | 07/06 | | |
NCT00254137: Cap/Iri Plus Cetuximab Compared to Cap/ox Plus Cetuximab in Patients With Metastatic Colorectal Cancer. |
|
|
| Completed | 2 | 92 | Europe | capecitabine, irinotecan, oxaliplatin, cetuximab | Ludwig-Maximilians - University of Munich, Merck Sharp & Dohme LLC, Sanofi, Pfizer, Hoffmann-La Roche | Metastatic Colorectal Cancer | | 11/06 | | |
NCT00083720: Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon or Rectal Cancer That is Refractory to Chemotherapy |
|
|
| Completed | 2 | 87 | US, Canada | cetuximab, Erbitux™ | Eli Lilly and Company, Bristol-Myers Squibb | Colorectal Neoplasms, Metastases, Neoplasm | 04/08 | 04/08 | | |
| Completed | 2 | 136 | Europe | FOLFOX-4+cetuximab, FOLFOX-4 | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), Merck Sharp & Dohme LLC | Colorectal Cancer | 02/09 | 02/09 | | |
NCT00503685: Study Using IMC-A12 (Cixutumumab) With or Without Cetuximab in Participants With Metastatic Colorectal Cancer Who Have Failed a Treatment Regimen That Consisted of a Prior Anti-EGFR Therapy |
|
|
| Completed | 2 | 65 | US | IMC-A12, Cixutumumab, LY3012217, cetuximab, Erbitux® | Eli Lilly and Company | Colorectal Cancer | 03/09 | 03/09 | | |
| Completed | 2 | 30 | Europe | Diprosone | Centre Oscar Lambret, Roche Pharma AG | Metastatic Colorectal Cancer, Non-Small-Cell Lung Carcinoma | 03/09 | 03/09 | | |
NCT00531115 / 2006-007062-11: Phase II Study to Evaluate Safety and Efficacy of Cetuximab in Combination With XELOX for 12 Weeks Followed by Maintenance Treatment With Cetuximab Plus Capecitabine as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer. |
|
|
| Terminated | 2 | 28 | Europe | cetuximab 5mg/ml | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), Merck Sharp & Dohme LLC | Metastatic Colorectal Cancer | 04/09 | 04/09 | | |
MK-7454-003, NCT00551213: A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, ) |
|
|
| Completed | 2 | 67 | NA | Robatumumab, Irinotecan, Cetuximab, Capecitabine, FOLFOX, CAPEOX/XELOX, FOLFIRI | Merck Sharp & Dohme LLC | Colorectal Cancer | 06/09 | 06/09 | | |
NCT00309179: A Phase II Study of the Safety and Efficacy of E7820 Plus Cetuximab in Colorectal Cancer, Preceded by a Run-in Study in Advanced Solid Tumors |
|
|
| Completed | 2 | 41 | US, Canada | E7820 plus cetuximab | Eisai Inc. | Advanced Colorectal Cancer | 12/09 | 02/17 | | |
NCT00614393: Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004) |
|
|
| Completed | 2 | 558 | NA | dalotuzumab, MK-0646, irinotecan hydrochloride, CAMPTOSAR®, cetuximab, ERBITUX®, placebo, placebo to dalotuzumab, normal saline solution | Merck Sharp & Dohme LLC | Metastatic Colorectal Cancer | 06/10 | 03/12 | | |
|
|
NCT01032291 / 2009-012665-61: A Study to Assess the Efficacy and Safety of Lenalidomide in Combination With Cetuximab in Pre-treated Patients With KRAS Mutant Colorectal Cancer |
|
|
| Terminated | 2 | 51 | Europe, RoW | cetuximab, Erbitux, lenalidomide, Revlimid | Celgene Corporation | Colorectal Cancer | 01/11 | 01/11 | | |
NCT00845039: A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab |
|
|
| Terminated | 2 | 4 | US | Cetuximab, Erbitux, LY2939777, Irinotecan, Camptosar, IMC-A12 (cixutumumab), Cixutumumab, LY3012217 | Eli Lilly and Company, NSABP Foundation Inc | Colon Cancer, Rectal Cancer | 02/11 | 02/11 | | |
NCT00522665: Phase I/Randomized Phase II Study of Second Line Therapy With Irinotecan + Cetuximab +/- RAD001 for Colorectal Cancer |
|
|
| Completed | 2 | 41 | US | Irinotecan, Cetuximab, RAD001 | Hoosier Cancer Research Network, Novartis Pharmaceuticals, Pfizer | Colorectal Cancer | 05/11 | 02/15 | | |
|
|
NCT00336856: Irinotecan and Cetuximab for Colorectal Cancer as Second Line Therapy |
|
|
| Completed | 2 | 35 | US | Cetuximab, Irinotecan | University of Pittsburgh, Bristol-Myers Squibb | Colon Cancer, Rectum Cancer | 06/11 | 06/11 | | |
| Completed | 2 | 31 | Europe | Capecitabine, Xeloda, Cetuximab, Erbitux | Austrian Breast & Colorectal Cancer Study Group, Hoffmann-La Roche, Merck Gesellschaft mbH, Austria | Rectal Cancer | 08/11 | 11/11 | | |
NCT00842257: Panitumumab in Cetuximab Refractory KRAS Wild-Type Colorectal Cancer |
|
|
| Completed | 2 | 20 | US | panitumumab, Vectibix | Massachusetts General Hospital, Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, Amgen | Colorectal Cancer | 12/11 | 12/11 | | |
NCT00766220: Yttrium Microspheres With Cetuximab Plus Irinotecan for Patients With Advanced Colorectal Cancer Mets to Liver |
|
|
| Withdrawn | 2 | 0 | US | SIR-spheres Agent Administration, Yttrium-90, Yttrium 90, Yttrium microspheres, Cetuximab, C225, Erbitux™, IMC-C225, Irinotecan, CPT-11 | M.D. Anderson Cancer Center, Sirtex Medical | Colon Cancer, Colorectal Cancer | 01/12 | 01/12 | | |
| Completed | 2 | 94 | Europe | BIBW 2992, Cetuximab | Boehringer Ingelheim | Colorectal Neoplasms | 03/12 | | | |
NCT01004159: Cetuximab Plus Irinotecan in Colorectal Cancer Patients Who Progressed After Failure With Cetuximab Plus Irinotecan |
|
|
| Terminated | 2 | 20 | US | cetuximab with irinotecan | Roswell Park Cancer Institute, Bristol-Myers Squibb | Colorectal Cancer | 05/12 | 05/12 | | |
NCT00577109: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Untreated Metastatic Colorectal Cancer. |
|
|
| Withdrawn | 2 | 0 | RoW | bevacizumab [Avastin], Irinotecan, Leucovorin, 5 FU, Cetuximab | Hoffmann-La Roche, Merck KGaA, Darmstadt, Germany | Colorectal Cancer | 06/12 | 06/12 | | |
NCT01703910 / 2012-001307-20: Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic |
|
|
| Completed | 2 | 29 | Europe | Arm A chemotherapy, Capecitabine, Cisplatin, Cetuximab, Doxorubicin, Fluorouracil, Gemcitabine, Irinotecan, Topotecan, Mitomycin C, Oxaliplatin, Paclitaxel, Docetaxel, Pemetrexed, Raltitrexed, Sorafenib, Erlotinib, Vinorelbine, Dasatinib, Etoposide, arm B chemotherapy | Centro Nacional de Investigaciones Oncologicas CARLOS III, Hospital Universitario de Fuenlabrada, Grupo Hospital de Madrid, Apices Soluciones S.L. | Adenocarcinoma of Colon, Adenocarcinoma of Rectum, Metastatic Disease | 11/12 | 12/14 | | |
NCT00611858: Cetuximab, 5-FU and Radiation as Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer |
|
|
| Terminated | 2 | 13 | US | Cetuximab, Erbitux, 5-Fluorouracil, 5-FU, Radiation, External Beam Radiation Therapy | Dana-Farber Cancer Institute, Massachusetts General Hospital, Beth Israel Deaconess Medical Center, Brigham and Women's Hospital, Bristol-Myers Squibb | Rectal Cancer | 12/12 | 09/16 | | |
| Terminated | 2 | 8 | Europe | Cetuximab, Erbitux, Irinotecan, Irinotecan eluting BEADS, DC Bead | Hans-Joachim Schmoll, MD, Biocompatibles UK Ltd | Colorectal Cancer | 12/12 | 05/15 | | |
| Completed | 2 | 47 | Europe | Cetuximab, Erbitux, Irinotecan, Camptosar, Oxaliplatin, Eloxatin, UFT, Tegafur, Uracil | The Christie NHS Foundation Trust, Merck Sharp & Dohme LLC | Metastatic Colorectal Cancer | 05/13 | 05/13 | | |
|
NCT01523639 / 2011-001010-34: A Randomized, Placebo-controlled, Double-blind Phase II Study Evaluating if Glucophage Can Avoid Liver Injury Due to Chemotherapy Associated Steatosis |
|
|
| Terminated | 2 | 8 | Europe | Metformin/Placebo, Glucophage | Austrian Breast & Colorectal Cancer Study Group, Merck Gesellschaft mbH, Austria | Colorectal Cancer, Steatohepatitis | 11/13 | 04/14 | | |
NCT00725400: Comparative Study of Cetuximab and Radiation Vs Surgery Before or After Radiation in Patients With Colorectal Carcinoma |
|
|
| Withdrawn | 2 | 450 | US | Cetuximab and Radiation Therapy, Erbitux and Radiotherapy, Surgery and Radiation Therapy, Surgery and Radiotherapy | American Scitech International, Eli Lilly and Company, Bristol-Myers Squibb | Colorectal Carcinoma | 02/14 | 02/14 | | |
APEC-Study, NCT00778830: Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab or FOLFOX Plus Cetuximab as First-line Therapy in Subjects With KRAS Wild-type Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 289 | RoW | Cetuximab, Erbitux, FOLFIRI, FOLFOX | Merck KGaA, Darmstadt, Germany, Merck Pte. Ltd., Singapore | Metastatic Colorectal Cancer | 04/14 | 04/14 | | |
|
|
|
|
|
NCT01652482 / 2011-005547-27: Safety and Efficacy Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI as Second Line Therapy in Participants With KRAS Wild-Type Metastatic Colorectal Cancer (mCRC) |
|
|
| Completed | 2 | 135 | US, Europe, RoW | 5-fluorouracil, ADRUCIL, Cetuximab, Erbitux, Irinotecan, CAMPTOSAR, Leucovorin, WELLCOVORIN, MEHD7945A | Genentech, Inc. | Colorectal Cancer | 11/14 | 11/14 | | |
| Completed | 2 | 73 | Europe | Cetuximab, Erbitux | Merck KGaA, Darmstadt, Germany, Merck, S.L., Spain | Colorectal Neoplasms | 12/14 | 12/14 | | |
| Completed | 2 | 139 | US | Cetuximab, Erbitux, 5-fluorouracil, 5-FU, Pelvic irradiation, Radiotherapy | US Oncology Research, Bristol-Myers Squibb, Eli Lilly and Company | Rectal Cancer | 01/15 | 01/15 | | |
|
NCT01925274 / 2013-002095-40: A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer |
|
|
| Terminated | 2 | 19 | Japan, US, Europe, RoW | PF-05212384, PKI-587, irinotecan, Camptosar, Campto, CPT-11, Cetuximab, Erbitux, Irinotecan | Pfizer | Metastatic Colorectal Cancer | 04/16 | 04/16 | | |
VISNU-2, NCT01640444 / 2012-000840-90: Influence of BRAF and PIK3K Status on the Efficacy of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFIRI) Plus Bevacizumab or Cetuximab in Patients With RAS Wild-type Metastatic Colorectal Carcinoma and < 3 Circulating Tumor Cells (CTC) |
|
|
| Completed | 2 | 240 | Europe | FOLFIRI + bevacizumab, FOLFIRI + cetuximab | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), Roche Pharma AG | Colorectal Cancer Metastatic | 11/18 | 11/18 | | |
NCT00226941: A Phase 1-2 Trial of Cetuximab in Combination With Oxaliplatin, Capecitabine, and Radiation Therapy Followed by Surgery for Locally-advanced Rectal Cancer |
|
|
| Terminated | 1/2 | 23 | US | Cetuximab, Erbitux, C225, IMC-C225, Oxaliplatin, Eloxatin, Capecitabine, Xeloda, Radiotherapy, XRT, Diphenhydramine hydrochloride (HCl), Benadryl, Unisom, Sominex | George Albert Fisher, Bristol-Myers Squibb | Rectal Cancer, Colo-rectal Cancer | 03/08 | 02/09 | | |
GEN206, NCT00677924: Zalutumumab With or Without Irinotecan Chemotherapy in Cetuximab-Refractory Colorectal Cancer |
|
|
| Terminated | 1/2 | 9 | Europe | Zalutumumab, HuMax-EGFr | Genmab | Colorectal Cancer | 04/09 | 04/09 | | |
NCT01086267: Safety and Efficacy Study of BMS-908662 Alone or in Combination With Cetuximab in Subjects With K-RAS or B-RAF Mutation Positive Advanced or Metastatic Colorectal Cancer |
|
|
| Completed | 1/2 | 17 | US, Canada | BMS-908662, Cetuximab | Bristol-Myers Squibb | Colorectal Cancer | 08/11 | 08/11 | | |
| Completed | 1/2 | 38 | US, Europe, RoW | Cetuximab, Erbitux, BMS-564717, Irinotecan, Brivanib, Brivanib Placebo | Bristol-Myers Squibb | Metastatic Colorectal Cancer (MCRC) | 12/12 | 12/12 | | |
|
NCT00908024: Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors |
|
|
| Terminated | 1/2 | 54 | US, Canada | BMS-754807, cetuximab (Erbitux®), Eributux® | Bristol-Myers Squibb | Colorectal Cancer, Head and Neck Cancer, Neoplasm Metastasis | 12/12 | 12/12 | | |
| Completed | 1/2 | 178 | US, Canada | PX-866 (SCCHN), Cetuximab (SCCHN), Erbitux, PX-866 (CRC), Cetuximab (CRC) | Cascadian Therapeutics Inc. | Incurable Metastatic Colorectal Carcinoma, Incurable Progressive, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | 11/13 | 01/14 | | |
|
|
NCT02278133 / 2014-002826-11: Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations |
|
|
| Completed | 1/2 | 20 | US, Canada, Europe, RoW | WNT974, LGX818, Cetuximab | Array BioPharma | Metastatic Colorectal Cancer | 05/16 | 06/17 | | |
